Search News Archives
Conferences | Events
Source BioScience invest €585,000 in stability storage with new state-of-the-art microbiology and sterility testing labs
New facilities expand services offering to Irish and International customers
Source Bioscience, an international provider of integrated laboratory services and products, has announced it has invested €585,000 in microbiology and sterility testing labs at its stability storage facility in Tramore, Co Waterford, Ireland. The investment expands the Company’s current service offering at the site, adding a comprehensive suite of microbiology and sterility testing services with the aim of reducing turnaround times to allow more rapid feedback to customers and to minimise risk when storing samples.
Accessible, high quality microbiology and sterility testing services are increasingly becoming a key requirement within the pharmaceutical, cosmetic and food industries in the UK and Ireland. The Company’s new labs boast the latest equipment served by highly trained personnel combined with a robust compliance ethos. A full suite of competitively priced tests is offered including sample pick up, market leading turnaround times and full reporting to meet customer’s requirements.
Source BioScience has been providing outsourced stability storage services for more than 40 years and has served the Irish market since 2007. Recently rebranded as Source Stability Storage Solutions, the Company offers a comprehensive portfolio of stability storage options, delivering 24/7 outsourced controlled environment storage for stability trials at all World Climatic ICH conditions, as well as bespoke conditions. The investment supports the further expansion of this offering in the Irish and European markets.
Brian Monaghan, Irish Account Manager of Source BioScience, said: “This investment brings major benefits to our customers. As a core offering, it means they can safely place products within our increasing number of ICH standard storage chambers, our fully trained and experienced microbiologists can access the chambers at required time points, test the product to establish acceptable limits and notify the client, with minimum disruption to samples. We are able to maintain a single quality agreement for a number of services which represents a major upside for our clients and offers great potential for reducing lead-times including the requirement for multiple audits, and minimises risk to products.”
Russell Wheatcroft, Commercial Director of Source Bioscience said: “We are thrilled to bring this investment and enhanced service to our valued current and future customers in Ireland. The funding is part of a two-stage process and we now look to expand our footprint in Ireland further by increasing the capacity of our Tramore facility by 40%. The Irish market is a key element to our expected growth in Europe and this investment will be critical in driving the Company through the next phase of its development.”
Source BioScience is a wholly owned subsidiary of Sherwood Holdings Limited (company registration number 10269474), having been acquired through a public-to-private transaction in September 2016, and was de-listed from the London Stock Exchange upon acquisition.
Serving a variety of markets, our multidisciplinary expertise includes:
- Outsourced Histopathology Reporting Services & Human Tissue Testing Services
- NGS (Next Generation Sequencing) & Sanger Sequencing Services
- Stability Storage Solutions
- Blood & Tissue Serology Product Manufacture
Source Stability Storage Solutions
We deliver outsourced controlled environment storage for stability trials at all World Climatic ICH conditions, as well as bespoke conditions. In addition, we offer photostability testing facilities, biostorage capabilities, contingency storage for disaster recovery and facilities for the conservation of heritage items and other precious materials.
Our stability storage rooms and cabinets are also available for purchasing, offering a wide array of options from cabinets to modular walk-in rooms. Some special projects can be considered.